Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS

GLMD Stock Annual Income Statement. Download in Excel

Galmed Pharmaceuticals Ltd. logo

Galmed Pharmaceuticals Ltd.

Sector: Healthcare   

Industry: Biotechnology

3.07
 
USD
  
0.17
  
(5.86%)
Previous close: 2.9  Open: 2.9  Bid: 3.05  Ask: 3.39
52 week range    
2.56   
   23.80
Mkt Cap: 2 M  Avg Vol (90 Days): 162,873
Peers   
ENDP / 
AERI / 
EVOK / 
Last updated: Friday 20th December 2024

Stock Rankings

53
Technical
21
Quality
How are these ranks calculated?
Search for a stock

Financials

GLMD Income Statement

Annual
Dec-14Dec-15Dec-16Dec-17Dec-18Dec-19Dec-20Dec-21Dec-22Dec-23
Basic EPS from continuing operations237.60.712.5
Basic EPS total237.60.712.5
Basic weighted shares outstanding57353.061669.063192.069374.0100764.0117302.0118226.0136645.025 M3 M
Cost of sales-144476.0-144476.0
Diluted EPS total237.60.712.5
Diluted normalized net income/share2.5
Diluted weighted shares outstanding100764.0117302.0118226.0136653.025 M3 M
Fees-919000.0
GainOnSaleOfSecurity7000.0217000.096000.014000.067000.0106000.0305000.0238000.0775000.0-13000.0
GeneralAndAdministrativeExpense2 M3 M3 M4 M4 M4 M4 M6 M5 M938000.0
Gross operating profit467000.01 M2 M144476.0144476.0-919000.0
Income before tax-9 M-11 M-17 M-12 M-10 M-20 M-29 M-32 M-18 M-7 M
Income taxes1000.0106000.075000.0
InsuranceAndClaims663000.0
Interest income40000.0253000.035000.0202000.0959000.02 M1 M375000.0
MiscOtherSpecialCharges65000.0934000.02 M1 M414000.0-215000.0
Net income from total operations-9 M-11 M-17 M-12 M-10 M-20 M-29 M-32 M-18 M-7 M
NetIncomeCommonStockholders-9 M-11 M-17 M-12 M-10 M-20 M-29 M-32 M-18 M-7 M
NetIncomeContinuousOperations-9 M-11 M-17 M-12 M-10 M-20 M-29 M-32 M-18 M-7 M
NetNonOperatingInterestIncomeExpense40000.0253000.035000.0202000.0959000.02 M1 M-275000.0640000.0
Normalized income-5 M
Operating income-9 M-11 M-17 M-12 M-11 M-22 M-30 M-33 M-18 M-8 M
Operating income before depreciation (EBITDA)-9 M-10 M-17 M-12 M-10 M-21 M-30 M-33 M-18 M-7 M
OperatingExpense-9 M-11 M-17 M-12 M13 M22 M30 M33 M18 M7 M
Other income net-7000.0-217000.0-96000.0-65000.0-934000.0-2 M-1 M-414000.0-490000.049000.0
OtherGandA2 M3 M3 M4 M4 M4 M4 M6 M5 M938000.0
OtherOperatingExpenses-49000.0-42000.0-4 M-3 M
RentAndLandingFees2 M3 M3 M4 M261000.0
Research & development expense7 M8 M14 M10 M8 M18 M26 M27 M13 M3 M
ResearchExpense7 M8 M14 M10 M8 M18 M26 M27 M13 M3 M
SalariesAndWages-2 M-1 M-2 M-2 M-2 M-2 M-1 M3 M
Selling Gen & administrative expense2 M3 M3 M4 M4 M4 M4 M6 M5 M938000.0
Total Income available for interest expense (EBIT)-9 M-11 M-17 M-12 M-10 M-20 M-30 M-33 M-18 M-7 M
Total common shares outstanding61669.061669.067495.080195.0116771.0117441.0118477.0139380.025 M
Total net income-9 M-11 M-17 M-12 M-10 M-20 M-29 M-32 M-18 M-7 M
Total ordinary shares529896.0529896.0529896.0529896.0529896.0529896.0529896.0529896.0529896.0529896.0
Total revenues467000.01 M2 M-919000.0
TotalExpenses-9 M-11 M-17 M-12 M13 M22 M30 M33 M18 M7 M
TotalRevenue467000.01 M2 M-919000.0
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.

MarketXLS is a complete Excel stock solution

Kevin Hsu

StockKevin.com

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel

Lloyd Lenase

Option Day Trader

MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.

Dave

Swing trader since 2011

I like to access historical closing prices on a particular date. That makes tracking performance easy.

Patrick Cusatis, Ph.D., CFA

Associate Professor of Finance - Penn State University